Evaluation of Lidocaine combined with Tramadol by intravesical retro-grade instillation for prevention of CRBD after general anesthesia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094743

Enrollment

Unknown

Registered

2024-12-26

Start date

2024-04-15

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CRBD

Interventions

Lidocaine group:Lidocaine

Tramadol group:Tramadol

Normal saline group:Normal saline

Lidocaine and Tramadol group:Lidocaine and Tramadol

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Female patients aged 18-60 years;American Society of Anesthesiologists (American society of anesthesiologists, ASA) Class I-II; Body mass index (Body mass index, BMI): 18.0-28.0 kg/m2; Elective uterine related general anesthesia surgery;The duration of the operation was 2 to 5 hours.

Exclusion criteria

Exclusion criteria: Refusal to sign a consent form; history of allergy to any anesthetic; communication or cognitive impairment; severe liver and kidney disease; history of bladder dysfunction or outflow obstruction; urinary tract infection or urinary tract surgery.

Design outcomes

Primary

Measure	Time frame
Incidence of CRBD immediately after tracheal extubation;	—

Secondary

Measure	Time frame
The incidence and severity of CRBD;Urethral pain score ;Ramsay rating;Postoperative nausea and vomiting incidence rate;	—

Countries

China

Contacts

Public ContactWANG FANG; QIAN BIN

Yancheng First People's Hospital

1278915937@qq.com+86 177 5907 3306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026